HIF1A and cancer: In looking for a clinically applicable inhibitor of HIF-1a for sarcomas, Dox is a very good candidate, given that Dox is already the most commonly used chemotherapeutic drug for sarcomas.46 However, the traditional means of delivering Dox, that is, at maximum tolerated doses, focuses on maximizing cancer cell cytotoxicity rather than maximizing HIF-1α blockade.